Sunday, September 6, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleSeeking Alpha· February 19, 2026

Oceaneering projects $390M–$440M EBITDA for 2026 as ADTech drives multiyear growth

View original at seekingalpha.com
Oceaneering projects $390M–$440M EBITDA for 2026 as ADTech drives multiyear growth Earnings Call Insights: Oceaneering International, Inc…
Opening lines of the source · Seeking Alpha · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Achieved 7% improvement in ROV pricing

    80% confidence
  • Interest in autonomous forklifts is high with adoption depending on customer readiness

    80% confidence
  • Not pursuing big industry consolidation M&A but sees potential for bolt-on technology acquisitions

    80% confidence
  • Oceaneering closed out 2025 with strong execution across the business, making continued progress against strategic priorities

    80% confidence
  • Government services lead times for ADTech projects vary quite a bit, with some ramping quickly and others requiring longer engineering and prototyping phases

    80% confidence
  • Organic capital expenditures for 2026 forecasted between $105 million and $115 million, with 40% allocated to growth and 60% to maintenance

    80% confidence
  • Cash balance increased to $689 million at year-end, further strengthening financial flexibility

    80% confidence
  • Achieved 140 basis points EBITDA margin expansion in 2025

    80% confidence
  • Net income of $178 million or $1.76 per share represents a 217% increase year-over-year, largely due to $156 million discrete tax benefit related to release of U.S. valuation allowances

    80% confidence
  • ROV uptime was 99% for the second consecutive year

    80% confidence
  • 2025 order intake was $3.7 billion with a book-to-bill ratio of 1.33

    80% confidence
  • Oceaneering's offshore, maritime, and space expertise translates across defense and energy with unique SUBSAFE certifications and capabilities in submarine sustainment and space systems

    80% confidence
  • Free cash flow for 2026 anticipated to be $100 million to $120 million, with year-over-year reduction primarily reflecting early receipt of $37 million in customer payments in Q4 2025

    80% confidence
  • IMDS integrates machine vision, machine learning, and AI for enhanced inspection capabilities that can be deployed subsea with ROVs

    80% confidence
  • 2026 EBITDA projected between $390 million and $440 million with year-over-year improvements in all segments except OPG

    80% confidence
  • Consolidated revenue in 2026 projected to grow in the low to mid-single-digit percentage range, with ADTech revenue improving significantly year-over-year

    80% confidence
  • Balance sheet strength and cash growth gives more flexibility and opportunity to do more when the time is right

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com